<DOC>
	<DOCNO>NCT01814839</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics pharmacodynamics ALN-TTRSC ( revusiran ) healthy volunteer subject .</brief_summary>
	<brief_title>A Phase 1 , Single- Multi-Dose , Dose Escalation Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Subcutaneously Administered ALN-TTRSC ( Revusiran ) Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Body mass index ( BMI ) must ≥ 16.5 kg/m2 ≤ 35.0 kg/m2 ; Female subject must nonchildbearing potential ; e.g. , postmenopausal premenopausal surgical sterilization ; Male subject agree use appropriate contraception ; Adequate blood count , liver renal function ; Nonsmokers least 3 month ; Willing give write informed consent willing comply study requirement ; Subject born Japan live outside Japan &lt; 10 year , subject 's biological parent grandparent fully Japanese bear Japan ( cohort 19 20 ) . Known human immunodeficiency virus ( HIV ) positive status know suspected systemic bacterial , viral , parasitic , fungal infection ; Subjects history multiple drug allergy intolerance SC injection ; History drug abuse and/or alcohol abuse ; Receiving investigational agent within 3 month prior study drug administration ; Considered unfit study Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
</DOC>